Randomized, Non-comparative Neoadjuvant Phase II Study in patients with ER+/HER2- Breast Cancer >= 2cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole

Project: Research

Project Description

NMA HREC Reference Number: HREC/56054/MonH-2019-180712(v1)
NMA SSA Reference Number: SSA/56054/MonH-2019-191782(v1)
Monash Health Ref: RES-19-0000-531A
StatusActive
Effective start/end date27/11/19 → 26/11/24
View all
View less

Keywords

  • clinical trial
  • treatment efficacy
  • breast cancer
  • phase 2 study
  • immunotherapy